What the Study Found (In Plain English)
Published in Journal of cardiovascular pharmacology and therapeutics (2012), this randomized controlled trial evaluating 78 human participants investigated: Postprandial triglyceride (TG) levels are easy to measure and are associated with future cardiovascular risk. Key clinical takeaway: The reduction in apo B/A1 was greater in the combination group (-32% ± 19% and -42% ± 13%, in the atorvastatin and combination groups, respectively, P = .02).
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Journal of cardiovascular pharmacology and therapeutics, 2012-03-15; N = 78; Rigor 82/100): The reduction in apo B/A1 was greater in the combination group (-32% ± 19% and -42% ± 13%, in the atorvastatin and combination groups, respectively, P = .02).
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.